Live feed06:45:00·6mPRReleasevia QuantisnowU.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)ByQuantisnow·Wall Street's wire, on your screen.MRK· Merck & Company Inc.Health Care
